| Molecular Pharming: future targets and aspirations. | |
| | |
MedLine Citation:
|
PMID: 21368584 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Molecular Pharming represents an unprecedented opportunity to manufacture affordable modern medicines and make these available at a global scale. The area of greatest potential is in the prevention of infectious diseases, particular in underdeveloped countries where access to medicines and vaccines has historically been limited. This is why, at St. George's, we focus on diseases such as HIV, TB and rabies, and aim to develop production strategies that are simple and potentially easy to transfer to developing countries. |
| | |
Authors:
|
Mathew Paul; Craig van Dolleweerd; Pascal M W Drake; Rajko Reljic; Harry Thangaraj; Tommaso Barbi; Elena Stylianou; Ilaria Pepponi; Leonard Both; Verena Hehle; Luisa Madeira; Varghese Inchakalody; Sammy Ho; Thais Guerra; Julian K-C Ma |
Related Documents
:
|
19726174 - Healthcare waste management in asia. 17033454 - Improving the regulation and management of low-activity radioactive wastes. 18595684 - Assessment of the status of municipal solid waste management in metro cities, state cap... 20613954 - Management of the adult with congenital adrenal hyperplasia. 21706124 - Perceptions and attitudes of japanese gynecologic cancer patients to kampo (japanese he... 7848234 - Spontaneous abortion: a medical approach to management. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2011-03-01 |
Journal Detail:
|
Title: Human vaccines Volume: 7 ISSN: 1554-8619 ISO Abbreviation: Hum Vaccin Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-07-12 Completed Date: 2011-12-16 Revised Date: 2012-03-01 |
Medline Journal Info:
|
Nlm Unique ID: 101265291 Medline TA: Hum Vaccin Country: United States |
Other Details:
|
Languages: eng Pagination: 375-82 Citation Subset: IM |
Affiliation:
|
Molecular Immunology Unit, Research Centre for Infection and Immunity, St. George's Hospital Medical School, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
AIDS Vaccines
/
biosynthesis Adjuvants, Immunologic / biosynthesis Animals Antibodies, Monoclonal / biosynthesis Antigen-Antibody Complex / immunology Clinical Trials as Topic / methods Developing Countries Drug Approval Drug Industry Humans Hydroponics Intellectual Property Mice Molecular Farming / methods* Plants / growth & development Plants, Genetically Modified / growth & development Rabies Vaccines / biosynthesis Recombinant Proteins / biosynthesis, immunology Technology Transfer Tuberculosis Vaccines / biosynthesis Vaccines / biosynthesis* |
| Grant Support | |
ID/Acronym/Agency:
|
//Wellcome Trust |
| Chemical | |
Reg. No./Substance:
|
0/AIDS Vaccines; 0/Adjuvants, Immunologic; 0/Antibodies, Monoclonal; 0/Antigen-Antibody Complex; 0/Rabies Vaccines; 0/Recombinant Proteins; 0/Tuberculosis Vaccines; 0/Vaccines |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pertussis knowledge, attitude and practices among European health care professionals in charge of ad...
Next Document: Recent advances of Cowpea mosaic virus-based particle technology.